HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Hartkoorn RC et al. Pharmacogenetics and Genomics 2010.
Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals. Rotger M et al. Circ Cardiovas Genet 2009.
Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Wangsomboonsiri W et al. CID 2010.
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Ciccacci C et al. Pharmacogenomics 2010.
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. Saitoh A et al. JAIDS 2010.
Common genetic variation and the control of HIV-1 in humans. Fellay J et al. PLoS Genet 2009.
Host genetics influences on HIV type-1 disease. Fellay J. Antivir Ther 2009.
A single amino acid difference in human APOBEC3H variants determines HIV-1 vif sensitivity. Zhen A et al. J Virol 2010.